Candel Therapeutics (CADL) Competitors $5.71 -0.24 (-4.03%) Closing price 04:00 PM EasternExtended Trading$5.76 +0.05 (+0.89%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CADL vs. EVO, AVDL, PAHC, XERS, CVAC, ELVN, CALT, COLL, NTLA, and PHVSShould you be buying Candel Therapeutics stock or one of its competitors? The main competitors of Candel Therapeutics include Evotec (EVO), Avadel Pharmaceuticals (AVDL), Phibro Animal Health (PAHC), Xeris Biopharma (XERS), CureVac (CVAC), Enliven Therapeutics (ELVN), Calliditas Therapeutics AB (publ) (CALT), Collegium Pharmaceutical (COLL), Intellia Therapeutics (NTLA), and Pharvaris (PHVS). These companies are all part of the "pharmaceutical products" industry. Candel Therapeutics vs. Its Competitors Evotec Avadel Pharmaceuticals Phibro Animal Health Xeris Biopharma CureVac Enliven Therapeutics Calliditas Therapeutics AB (publ) Collegium Pharmaceutical Intellia Therapeutics Pharvaris Candel Therapeutics (NASDAQ:CADL) and Evotec (NASDAQ:EVO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership. Is CADL or EVO more profitable? Candel Therapeutics has a net margin of 0.00% compared to Evotec's net margin of -20.14%. Evotec's return on equity of -16.94% beat Candel Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Candel TherapeuticsN/A -41.00% -26.81% Evotec -20.14%-16.94%-8.14% Do insiders and institutionals have more ownership in CADL or EVO? 13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 5.8% of Evotec shares are held by institutional investors. 16.6% of Candel Therapeutics shares are held by insiders. Comparatively, 1.0% of Evotec shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has better valuation & earnings, CADL or EVO? Candel Therapeutics has higher earnings, but lower revenue than Evotec. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCandel Therapeutics$120K2,612.33-$55.18M-$0.69-8.28Evotec$777.33M1.63-$212.18MN/AN/A Does the media favor CADL or EVO? In the previous week, Evotec had 2 more articles in the media than Candel Therapeutics. MarketBeat recorded 4 mentions for Evotec and 2 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of 0.14 beat Evotec's score of -0.09 indicating that Candel Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Evotec 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate CADL or EVO? Candel Therapeutics currently has a consensus price target of $22.00, suggesting a potential upside of 285.29%. Evotec has a consensus price target of $5.40, suggesting a potential upside of 51.26%. Given Candel Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Candel Therapeutics is more favorable than Evotec.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Candel Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Evotec 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more risk and volatility, CADL or EVO? Candel Therapeutics has a beta of -0.88, suggesting that its stock price is 188% less volatile than the S&P 500. Comparatively, Evotec has a beta of 1.67, suggesting that its stock price is 67% more volatile than the S&P 500. SummaryCandel Therapeutics beats Evotec on 10 of the 15 factors compared between the two stocks. Get Candel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CADL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CADL vs. The Competition Export to ExcelMetricCandel TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$326.63M$3.12B$5.82B$9.75BDividend YieldN/A2.24%4.40%4.08%P/E Ratio-8.2820.6430.1425.84Price / Sales2,612.33390.51469.15120.64Price / CashN/A43.2325.7828.79Price / Book4.059.649.425.99Net Income-$55.18M-$54.08M$3.27B$265.29M7 Day Performance-4.19%2.62%2.05%2.53%1 Month Performance-18.66%4.05%3.58%0.92%1 Year Performance0.53%9.48%30.09%18.70% Candel Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CADLCandel Therapeutics2.3152 of 5 stars$5.71-4.0%$22.00+285.3%+4.8%$326.63M$120K-8.2860EVOEvotec1.5238 of 5 stars$3.68-2.1%$5.40+46.7%+8.7%$1.34B$862.40M0.004,827AVDLAvadel Pharmaceuticals2.6594 of 5 stars$13.48-1.5%$18.67+38.5%-7.6%$1.33B$169.12M-449.3370PAHCPhibro Animal Health3.4286 of 5 stars$31.25+1.9%$24.40-21.9%+55.0%$1.24B$1.02B40.061,940News CoverageUpcoming EarningsXERSXeris Biopharma3.3949 of 5 stars$7.36-4.2%$6.58-10.6%+169.1%$1.24B$203.07M-35.05290News CoverageAnalyst RevisionCVACCureVac4.6185 of 5 stars$5.45-0.5%$6.83+25.4%+64.4%$1.23B$579.18M5.92880Earnings ReportELVNEnliven Therapeutics2.8149 of 5 stars$19.75-2.3%$41.20+108.6%-9.3%$1.20BN/A-9.8850CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180COLLCollegium Pharmaceutical2.288 of 5 stars$38.19+1.2%$42.33+10.8%+7.9%$1.19B$631.45M36.72210News CoverageNTLAIntellia Therapeutics4.6053 of 5 stars$10.73-2.4%$29.05+170.8%-55.5%$1.18B$57.88M-2.29600Positive NewsInsider TradeGap UpPHVSPharvaris2.9484 of 5 stars$22.16-0.6%$35.60+60.6%+29.5%$1.17BN/A-6.6030 Related Companies and Tools Related Companies EVO Competitors AVDL Competitors PAHC Competitors XERS Competitors CVAC Competitors ELVN Competitors CALT Competitors COLL Competitors NTLA Competitors PHVS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CADL) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Candel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Candel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access